[go: up one dir, main page]

AR003919A1 - POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT - Google Patents

POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT

Info

Publication number
AR003919A1
AR003919A1 ARP960101095A AR10109596A AR003919A1 AR 003919 A1 AR003919 A1 AR 003919A1 AR P960101095 A ARP960101095 A AR P960101095A AR 10109596 A AR10109596 A AR 10109596A AR 003919 A1 AR003919 A1 AR 003919A1
Authority
AR
Argentina
Prior art keywords
protein
accessory protein
human
interleukin
antibody
Prior art date
Application number
ARP960101095A
Other languages
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR003919A1 publication Critical patent/AR003919A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta invención hace disponible por primera vez una proteína accesoria del receptor IL-1 humana que puede ser usado para regular los efectos de IL-1. Elagregado de esta proteina inhibe el efecto de IL-1 en las células.Por lo tanto, un aspecto de lainvención es proveer dicha proteína para el tratamiento decondiciones patológicas causadas por un exceso de actividad de las células que responden a IL-1 mediante el agregado de una cantidad de proteína accesoria delreceptor IL-1R humana (IL-1R AcP)suficiente para inhibir la activación de células por IL-1. Esta metodología también puede ser modificada, y la proteínaaccesoria puede ser usada como agente de rastreo para productos farmacéuticos. La invención comprende además el polinucleótido que codifica a dicha proteína,un vector, una célula huésped, una proteína de fusión que comprende dicha proteína, un anticuerpo que se une específicamente a dicha proteína, unacomposición farmacéutica que la comprende, un procedimiento parala preparación de dicha proteína y el empleo de dicha proteína como sustancia terapéutica parael tratamiento de respuestas inflamatorias o inmunológicas y/o para la regulación y prevención de las actividades inflamatorias o inmunológicas delainterleuquina-1, entre otras afecciones y/o enfermedades.This invention makes available for the first time a human IL-1 receptor accessory protein that can be used to regulate the effects of IL-1. Aggregation of this protein inhibits the effect of IL-1 on cells. Therefore, one aspect of the invention is to provide said protein for the treatment of pathological conditions caused by excess activity of cells that respond to IL-1 by adding of an amount of human IL-1R receptor accessory protein (IL-1R AcP) sufficient to inhibit the activation of cells by IL-1. This methodology can also be modified, and the accessory protein can be used as a tracking agent for pharmaceuticals. The invention further comprises the polynucleotide encoding said protein, a vector, a host cell, a fusion protein comprising said protein, an antibody that specifically binds to said protein, a pharmaceutical composition comprising it, a process for the preparation of said protein and the use of said protein as a therapeutic substance for the treatment of inflammatory or immunological responses and / or for the regulation and prevention of inflammatory or immunological activities of interleukin-1, among other conditions and / or diseases.

ARP960101095A 1995-01-23 1996-01-19 POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT AR003919A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
AR003919A1 true AR003919A1 (en) 1998-09-30

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960101095A AR003919A1 (en) 1995-01-23 1996-01-19 POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT

Country Status (19)

Country Link
EP (1) EP0808365A1 (en)
JP (1) JPH10512453A (en)
AR (1) AR003919A1 (en)
AU (1) AU4537096A (en)
BR (1) BR9606837A (en)
CA (1) CA2210724A1 (en)
CO (1) CO4480033A1 (en)
CZ (1) CZ208197A3 (en)
EA (1) EA199700265A1 (en)
FI (1) FI973089A0 (en)
HU (1) HUP9702458A2 (en)
IL (1) IL116796A0 (en)
MX (1) MX9705501A (en)
NO (1) NO973404D0 (en)
PE (1) PE64396A1 (en)
PL (1) PL321538A1 (en)
TR (1) TR199700652T1 (en)
WO (1) WO1996023067A1 (en)
ZA (1) ZA96333B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
AU741330B2 (en) * 1997-04-30 2001-11-29 F. Hoffmann-La Roche Ag Rat ST38.2 chemokine
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
AU755391B2 (en) 1997-12-23 2002-12-12 Immunex Corporation SIGIRR DNA and polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US7049095B2 (en) 2000-10-31 2006-05-23 Immunex Corporation DNA encoding IL-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
EP3492100B1 (en) 2001-06-26 2021-12-08 Amgen Inc. Antibodies to opgl
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
PL374118A1 (en) * 2001-08-07 2005-10-03 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
PL377091A1 (en) 2002-09-06 2006-01-23 Amgen, Inc. Therapeutic human anti-il-1r1 monoclonal antibody
AU2005231822B2 (en) 2004-04-02 2011-07-21 Swedish Orphan Biovitrum Ab (Publ) Methods of reducing aggregation of IL-1ra
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2607113C (en) * 2004-05-05 2013-11-12 Valorisation-Recherche, Societe En Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
US20090048161A1 (en) * 2005-05-05 2009-02-19 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
WO2009120903A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
JP5940093B2 (en) 2011-01-19 2016-06-29 カンタージア アクチエボラーグ Anti-IL-1RAP antibodies and their use to treat humans
RU2671980C2 (en) 2011-02-09 2018-11-08 Натера, Инк. Methods for non-invasive prenatal ploidy calling
EP2723365A1 (en) * 2011-06-21 2014-04-30 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
GB201403875D0 (en) † 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
EP3313887A2 (en) 2015-06-26 2018-05-02 MAB Discovery GmbH Monoclonal anti-il-1racp antibodies
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
US11773434B2 (en) 2017-06-20 2023-10-03 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free DNA
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
JP7573443B2 (en) 2018-04-14 2024-10-25 ナテラ， インコーポレイテッド Methods for cancer detection and monitoring using personalized detection of circulating tumor dna - Patents.com
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
TW202021618A (en) 2018-08-17 2020-06-16 美商２３與我有限公司 Anti-il1rap antibodies and methods of use thereof
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (en) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions and methods for inhibiting cytokine-release syndrome
US20240224961A1 (en) * 2021-05-28 2024-07-11 Biocytogen Jiangsu Co., Ltd. Genetically modified non-human animal with human or chimeric il1rap
TW202428613A (en) 2022-09-21 2024-07-16 法商賽諾菲生物技術公司 Humanized anti-il-1r3 antibody and methods of use

Also Published As

Publication number Publication date
FI973089A7 (en) 1997-07-22
NO973404L (en) 1997-07-23
CA2210724A1 (en) 1996-08-01
IL116796A0 (en) 1996-05-14
EA199700265A1 (en) 1998-04-30
WO1996023067A1 (en) 1996-08-01
NO973404D0 (en) 1997-07-23
MX9705501A (en) 1997-10-31
CZ208197A3 (en) 1997-11-12
PE64396A1 (en) 1997-01-28
BR9606837A (en) 1998-05-26
CO4480033A1 (en) 1997-07-09
HUP9702458A2 (en) 1998-04-28
EP0808365A1 (en) 1997-11-26
AU4537096A (en) 1996-08-14
FI973089L (en) 1997-07-22
TR199700652T1 (en) 1998-02-21
PL321538A1 (en) 1997-12-08
ZA96333B (en) 1996-07-23
FI973089A0 (en) 1997-07-22
JPH10512453A (en) 1998-12-02

Similar Documents

Publication Publication Date Title
AR003919A1 (en) POLYNUCLEOTIDE THAT CODES FOR A HUMAN ACCESSORY PROTEIN FOR INTERLEUKIN-1 RECEPTOR, SUCH ACCESSORY PROTEIN, A VECTOR, AN ANTIBODY THAT Binds TO SUCH PROTEIN, A PHARMACEUTICAL COMPOSITION THAT SUPPORTS IT
Vitaliano et al. The relative importance of risk factors in nonmelanoma carcinoma
Rosenthal et al. Seasonal affective disorders
Joling et al. The cost-effectiveness of a family meetings intervention to prevent depression and anxiety in family caregivers of patients with dementia: a randomized trial
BR0213846A (en) methods of selectively inducing apoptosis in dr5-expressing target cells, inhibiting proliferation of dr5-expressing target cells, and treating a patient having an inflammatory disease or autoimmune disease;
EA200900272A1 (en) COMBINATIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CELL PROLIFERATION, MIGRATION OR APOPTOTIS OF MYELOMA CELLS OR ANGIOGENESIS
ES2194935T3 (en) STABLE PREPARATIONS OF TRANSGLUTAMINASE AND PROCEDURE FOR PREPARATION.
AR100225A2 (en) ANTI-FACTOR D HUMANIZED ANTIBODIES AND USES OF THE SAME
RU2010108429A (en) MMR-9 REGULATORS AND THEIR APPLICATION
Fagan Remembering the lessons of basic pharmacology
CY1109868T1 (en) CD81 PROFESSIONAL SUBSCRIPTION PROTECTOR C
GT200300294A (en) INDAZOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS TO INHIBIT PROTEINKINES AND PROCEDURES FOR USE
FR2819723B1 (en) HALOGEN COMPOSITION, PREPARATION METHOD AND USES THEREOF
Abelaira et al. Ketamine exhibits different neuroanatomical profile after mammalian target of rapamycin inhibition in the prefrontal cortex: the role of inflammation and oxidative stress
BRPI0311511A8 (en) "LIQUID PHARMACEUTICAL PREPARATIONS, AND THEIR APPLICATION".
DE69422712D1 (en) TRIS-PLATINUM COMPLEXES
ES2061521T3 (en) PROTEINS WITH GLUTATION-S-TRANSFERASE ACTIVITY, DNA SEQUENCES, ANTIBODIES, POXVIRUSES AND MEDICINES FOR THE PREVENTION OF EQUISTOSOMIASIS.
ES2095216T3 (en) TRANSDERMAL SYSTEM WITH STAGED ASSIGNMENT OF THE ACTIVE SUBSTANCE AND ITS USE FOR THE LOCAL OR SYSTEMIC COSMETIC ADMINISTRATION OF THE ACTIVE SUBSTANCE.
Mazzara et al. Atypical primary varicella rash: Systematic literature review
Grimes et al. Childhood vitiligo: clinical spectrum and therapeutic approaches
ES2110057T3 (en) MEDICINAL COMPOSITION CONTAINING TCF-II.
Bilgiç et al. Possible atomoxetine-induced vitiligo: a case report
Goldstein et al. Combined use of benserazide and carbidopa in Parkinson's disease
AR023464A1 (en) NEW NOVELS OF THE OX2 PROTEIN OF MAMMER AND RELATED REAGENTS
Baliño et al. Role of CA2+/calmodulin on ethanol neurobehavioral effects